| Dr Steven David Thies, MD | |
|
2555 Court Dr Ste 450, Gastonia, NC 28054-2191 | |
| (704) 671-7652 | |
| (704) 671-7656 |
| Full Name | Dr Steven David Thies |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 32 Years |
| Location | 2555 Court Dr Ste 450, Gastonia, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104821669 | NPI | - | NPPES |
| 2062802 | Other | FIRST HEALTH | |
| 297391 | Other | MAMSI | |
| 790625X | Medicaid | NC | |
| 194355 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 19435 (South Carolina) | Secondary |
| 208600000X | Surgery | 9701170 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Coastal Carolina Hospital | Hardeeville, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Onslow Memorial Hospital Inc | 1456252899 | 50 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).
At first glance airplane wings and human hearts have little in common, but, say a team of European researchers, a technology used to measure airflow over wings can now be used to help keep hearts in working order.
Seeking to bring clarity to the debate on mobile phone use, researchers from the University of Essex have published the results of an investigation into the effects of mobiles on attention.
The evolutionary processes underlying metastasis-the development of secondary malignant growths away from the primary tumor site-in human patients are still incompletely understood.
› Verified 6 days ago
| Entity Name | Caromont Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356314272 PECOS PAC ID: 3577476258 Enrollment ID: O20031201000070 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).
At first glance airplane wings and human hearts have little in common, but, say a team of European researchers, a technology used to measure airflow over wings can now be used to help keep hearts in working order.
Seeking to bring clarity to the debate on mobile phone use, researchers from the University of Essex have published the results of an investigation into the effects of mobiles on attention.
The evolutionary processes underlying metastasis-the development of secondary malignant growths away from the primary tumor site-in human patients are still incompletely understood.
› Verified 6 days ago
| Entity Name | Onslow Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679535496 PECOS PAC ID: 1456252899 Enrollment ID: O20040119000016 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).
At first glance airplane wings and human hearts have little in common, but, say a team of European researchers, a technology used to measure airflow over wings can now be used to help keep hearts in working order.
Seeking to bring clarity to the debate on mobile phone use, researchers from the University of Essex have published the results of an investigation into the effects of mobiles on attention.
The evolutionary processes underlying metastasis-the development of secondary malignant growths away from the primary tumor site-in human patients are still incompletely understood.
› Verified 6 days ago
| Entity Name | Surgical Specialists Of Charlotte Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073599734 PECOS PAC ID: 3779519285 Enrollment ID: O20050714001059 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).
At first glance airplane wings and human hearts have little in common, but, say a team of European researchers, a technology used to measure airflow over wings can now be used to help keep hearts in working order.
Seeking to bring clarity to the debate on mobile phone use, researchers from the University of Essex have published the results of an investigation into the effects of mobiles on attention.
The evolutionary processes underlying metastasis-the development of secondary malignant growths away from the primary tumor site-in human patients are still incompletely understood.
› Verified 6 days ago
| Entity Name | Vidant Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648731 PECOS PAC ID: 0345343893 Enrollment ID: O20070321000445 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).
At first glance airplane wings and human hearts have little in common, but, say a team of European researchers, a technology used to measure airflow over wings can now be used to help keep hearts in working order.
Seeking to bring clarity to the debate on mobile phone use, researchers from the University of Essex have published the results of an investigation into the effects of mobiles on attention.
The evolutionary processes underlying metastasis-the development of secondary malignant growths away from the primary tumor site-in human patients are still incompletely understood.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven David Thies, MD Po Box 744786, Atlanta, GA 30374-4786 Ph: (704) 834-2450 | Dr Steven David Thies, MD 2555 Court Dr Ste 450, Gastonia, NC 28054-2191 Ph: (704) 671-7652 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).
At first glance airplane wings and human hearts have little in common, but, say a team of European researchers, a technology used to measure airflow over wings can now be used to help keep hearts in working order.
Seeking to bring clarity to the debate on mobile phone use, researchers from the University of Essex have published the results of an investigation into the effects of mobiles on attention.
The evolutionary processes underlying metastasis-the development of secondary malignant growths away from the primary tumor site-in human patients are still incompletely understood.
› Verified 6 days ago
Kim Leigh Crosby, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2391 Court Dr, Ste 110, Gastonia, NC 28054 Phone: 704-853-3330 Fax: 704-853-8951 | |
Dr. Mark Aaron Kuzich, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2555 Court Dr Ste 450, Gastonia, NC 28054 Phone: 704-671-7652 Fax: 704-671-7656 | |
Dr. Daniel L Mcclellan, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 2544 Court Dr, Suite G, Gastonia, NC 28054 Phone: 704-864-7821 Fax: 704-865-0519 | |
Dr. Demar Austin Neal, M.D., F.A.C.S. Surgery Medicare: Medicare Enrolled Practice Location: 2555 Court Dr, Suite 450, Gastonia, NC 28054 Phone: 704-671-7652 Fax: 704-671-7656 | |
Dr. Eric Tomson Emerson, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 649 N New Hope Rd, Gastonia, NC 28054 Phone: 704-866-4005 Fax: 704-866-0450 | |
Anthony Edward Raspanti, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2555 Court Dr, Suite 450, Gastonia, NC 28054 Phone: 704-671-7652 Fax: 704-671-7656 |